Moshkevich Solomon sold $569K of NTRA

Moshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 2,214 shares of Natera, Inc. (NTRA) at an average of $257.00 ($254.07–$260.49, $0.57M total) across 2 trades over 2026-07-27 to 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moshkevich Solomon
Published Jul 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosed event is an open-market sale totaling $568,996.59 across two trades, executed under a pre-arranged Rule 10b5-1 plan. No new company fundamentals are disclosed in the text.

02

Market read

Traders may monitor insider activity for sentiment, but the 10b5-1 structure and lack of new fundamentals suggest low immediate impact.

03

What to watch

The article provides only the sale details, not any concurrent buy activity, total planned volume, or whether the officer’s remaining holdings are part of a larger scheduled program.

Relevance 4/10Novelty 3/10Timing: after-hours/filing update on 2026-07-29 for trades dated 2026-07-27 to 2026-07-28

Background

The article is an SEC Form 4 insider transaction for Natera, Inc. reported by an officer (President, ClinicalDiagnostics).

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera insider Moshkevich Solomon sold about $569K of NTRA shares via an open-market sale under a 10b5-1 plan on July 27-28.

Expected impact

Likely limited near-term price impact; any effect would be sentiment-driven and typically fades.

Evidence & confidence

The filing is a Form 4 open-market sale by an officer with a pre-arranged 10b5-1 plan, with no accompanying new operational, regulatory, or financial disclosure.

Market effects

Minimal. Single-insider 10b5-1 sales rarely change sector risk premia for diagnostics/genomics names.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with periods of valuation risk or personal liquidity needs, so some traders may still front-run a short-term sentiment dip.

Key entities

  • Natera, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Moshkevich Solomon

    Officer (President, ClinicalDiagnostics) who sold NTRA shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.